Abbott, a global leader in medical device technology, has announced a significant integration of its LibreView software with Epic EHR systems, a move aimed at transforming diabetes management across the U.S. healthcare landscape. With this collaboration, more than 575,000 healthcare providers now have direct access to glucose data from Abbott’s Freestyle Libre continuous glucose monitoring (CGM) systems via patient electronic health records.
Epic EHR: Leading the Digital Healthcare Revolution
Epic Systems is currently the top EHR provider in the U.S., enabling hospitals and clinics to maintain and update comprehensive digital records of patient health histories. According to recent data from Klas Research, Epic achieved its largest-ever net gain in hospital market share last year, further cementing its dominance over competitors like Oracle in the EHR space.
This dominance means that the integration with Epic can have a wide-reaching impact, reaching up to 280 million patients, by making it easier for physicians to access and act on real-time health data.
What Abbott’s Integration Means for Providers and Patients
Abbott’s integration of LibreView with Epic EHR systems is designed to reduce time spent by healthcare providers searching for glucose data. It also fosters better patient-provider collaboration, giving clinicians the ability to make more informed decisions during consultations.
Glucose readings from Freestyle Libre CGMs will now appear directly in patients’ digital charts within Epic, allowing for a more holistic view of a patient’s health. This seamless access to blood sugar trends is especially valuable for managing both Type 1 and Type 2 diabetes more proactively and effectively.
The Global Impact and Market Competition
Abbott reports that over 6 million people globally use its Freestyle Libre CGM systems. In the first quarter alone, the company recorded $1.7 billion in CGM sales, reflecting an 18.3% year-over-year growth. These numbers demonstrate strong momentum in the digital health market.
However, Abbott is not alone in this race. Its main competitor, Dexcom, a medtech firm also specializing in CGM technology, projects $4.6 billion in sales for 2025. Both companies are expanding beyond their initial focus on the Type 1 diabetes market, seeking innovation in areas such as AI-powered over-the-counter CGM devices, integration with wearable tech like smart rings, and connectivity with insulin pumps.
A New Era for Diabetes Care
As the demand for real-time health monitoring grows, especially for chronic conditions like diabetes, integrations like Abbott’s with Epic EHR systems represent a critical step toward streamlined digital care. By minimizing data silos and enhancing accessibility, both providers and patients stand to benefit from faster decision-making, improved disease management, and reduced clinical workloads.
This move underscores how technology partnerships can bridge the gap between medical devices and electronic records, ultimately transforming chronic disease care in an increasingly connected healthcare ecosystem.
